12/19
11:12 am
slrx
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Low
Report
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
12/18
07:50 am
slrx
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
Low
Report
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
12/17
04:37 pm
slrx
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/17
08:57 am
slrx
NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio [Yahoo! Finance]
Medium
Report
NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio [Yahoo! Finance]
12/11
04:22 pm
slrx
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/5
04:27 pm
slrx
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/1
08:00 am
slrx
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
Medium
Report
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
11/29
03:38 pm
slrx
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/24
01:53 pm
slrx
Salarius Pharmaceuticals (NASDAQ:SLRX) is now covered by analysts at
Weiss Ratings. They set a "sell (e+)" rating on the stock.
Low
Report
Salarius Pharmaceuticals (NASDAQ:SLRX) is now covered by analysts at
Weiss Ratings. They set a "sell (e+)" rating on the stock.
11/19
04:45 pm
slrx
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” [Yahoo! Finance]
Low
Report
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” [Yahoo! Finance]
11/19
02:42 pm
slrx
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
Medium
Report
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
11/13
07:07 pm
slrx
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger [Yahoo! Finance]
Low
Report
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger [Yahoo! Finance]
11/13
08:45 am
slrx
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
Low
Report
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
11/11
09:18 am
slrx
Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering
High
Report
Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering
10/13
09:10 am
slrx
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements [Yahoo! Finance]
Low
Report
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements [Yahoo! Finance]
10/13
09:09 am
slrx
Salarius regains full Nasdaq compliance ahead of planned merger with Decoy Therapeutics [Seeking Alpha]
Low
Report
Salarius regains full Nasdaq compliance ahead of planned merger with Decoy Therapeutics [Seeking Alpha]
10/13
08:45 am
slrx
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
Medium
Report
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements